BI launches hepatitis C website
RIDGEFIELD, Conn. — Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.
BI announced the launch of HepCRedefined.com, which it describes as an online portal to help improve the lives of those living with the virus through education, information and understanding.
"The entire HCV community is in need of simple tools and resources to talk about the disease in an informed, supportive way," said Hepatitis Education Project executive director Michael Ninburg, who contributed to the website’s development. "There is information about HCV across the web, but HepCRedefined.com is designed to aggregate straightforward and accurate information in a single virtual destination."
FDA panel recommends approval for two Novo Nordisk insulin products
BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.
Novo Nordisk said the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.
The FDA is not bound by advisory committee votes when deciding whether or not to approve a drug, but usually follows them. However, the panel also voted unanimously to recommend that after approval, a post-marketing trial be conducted on the drugs to assess their effects on cardiovascular health.
"The positive vote from the advisory committee marks an important step towards making insulin degludec and insulin degludec-insulin aspart available to patients with diabetes in the US," Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. "We look forward to completing the regulatory process with the agency, including the design of the post-approval cardiovascular outcomes trial."
Allscripts hints at possible acquisition
CHICAGO — Electronic health record firm Allscripts may be looking at buyout offers from other companies, Allscripts CEO Glen Tullman said Thursday when the company announced its third-quarter 2012 earnings.
"We are confirming today that in light of the ongoing interest expressed in the company by third parties, the company is evaluating strategic alternatives," Tullman said. "Regardless of the outcome of this process, Allscripts’ primary focus is and will continue to be serving our clients through our industry-leading technology, services and the support we provide to 1,500 hospitals and over 50,000 ambulatory physician practices and post-acute providers with whom we do business."
The company said there was "no assurance" that it would be acquired and that it did not intent to comment further publicly.
The company reported sales of $360.7 million, down from $363.7 million in third-quarter 2011, and profits of $9.4 million, down from $19.1 million a year ago.